MIRM
Mirum Pharmaceuticals, Inc.- Healthcare
- Biotechnology
- $5.99B market cap
Forecast run · Sep 14, 2026Upside rank 1260 of 3,136
Model Signal
ForecastQ Daily Probabilities
40.1%
40.6%
17.5%
Analyst Consensus
Recommendation1.94/5 Buy
Last price$98.22
Price target$140.20
Implied move+42.7%
Analysts18
ForecastQ Portfolios
MIRM is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.